ERBB2 and breast cancer: Specifically, concerning HER2+ BC, and as already outlined before, the currently selected emerging therapies designed to overcome trastuzumab resistance aim to target critical downstream signaling molecules whose dysregulation is significantly implicated in sustaining oncogenic HER2 signaling and the maintenance/survival of BCSCs.